<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
    <item congress="117" measure-type="hr" measure-number="3662" measure-id="id117hr3662" originChamber="HOUSE" orig-publish-date="2021-06-01" update-date="2022-07-21">
        <title>Patient Access to Urgent-Use Pharmacy Compounding Act of 2021</title>
        <summary summary-id="id117hr3662v00" currentChamber="HOUSE" update-date="2022-07-21">
            <action-date>2021-06-01</action-date>
            <action-desc>Introduced in House</action-desc>
            <summary-text><![CDATA[ <p><strong>Patient Access to Urgent-Use Pharmacy Compounding Act of 2021</strong></p> <p>This bill relaxes certain requirements for compounding drugs that are facing shortages. </p> <p>Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements.</p> <p>This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for urgent medical need not involving a specific patient if, among other things, (1) the prescriber certifies that they are unable to obtain, despite reasonable attempts, certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug.</p> <p>Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists. </p>]]></summary-text>
        </summary>
    </item>
    <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
        <dc:format>text/xml</dc:format>
        <dc:language>EN</dc:language>
        <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
        <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
        <dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
    </dublinCore>
</BillSummaries>
